original ) (raw )Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial
Hassan Almoazen
Child Neurology Open
View PDFchevron_right
A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blinded, randomised, placebo-controlled trial
Jasna Jančić
British Journal of Dermatology, 2023
View PDFchevron_right
Topical rapamycin for angiofibromas in patients with tuberous sclerosis: how does it work in clinical practice
Maria Ekbäck , Plastic and Aesthetic Research
Plastic and Aesthetic Research, 2016
View PDFchevron_right
Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin
Audrey Woerner
View PDFchevron_right
Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex
John Slopis , Audrey Woerner
Drugs in R&D, 2012
View PDFchevron_right
Characterization and Management of Facial Angiofibroma Related to Tuberous Sclerosis Complex in the United States: Retrospective Analysis of the Natural History Database
Eric Beresford
2022
View PDFchevron_right
Topical Rapamycin
Joyce Teng
Archives of Dermatology, 2010
View PDFchevron_right
Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?
Wei-yu Chen
PLoS ONE, 2014
View PDFchevron_right
Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma
Juan Ruano
Journal of the European Academy of Dermatology and Venereology, 2011
View PDFchevron_right
Topical rapamycin (sirolimus) for facial angiofibromas
Bhushan Madke
Indian Dermatology Online Journal, 2013
View PDFchevron_right
Managing Different Spectrums of Tuberous Sclerosis Facial Angiofibroma: A Report of Two Cases
syafiq mohamad
Cureus
View PDFchevron_right
Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed
Karine Andrieux
Pharmaceutics
View PDFchevron_right
TREATMENT OF FACIAL ANGIOFIBROMAS OF TUBEROUS SCLEROSIS WİTH RADIOFREQUENCY DESSICATION AND COAGULATION Case presentation
Romanian Journal of Clinical and Experimental Dermatology ROJCED
View PDFchevron_right
Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas
Karine Andrieux
European Journal of Hospital Pharmacy
View PDFchevron_right
Topical Rapamycin as a Treatment for Fibrofolliculomas in Birt-Hogg-Dubé Syndrome: A Double-Blind Placebo-Controlled Randomized Split-Face Trial
Martin Prins
PLoS ONE, 2014
View PDFchevron_right
Dermoscopy of Facial Angiofibromas in Four Patients of Skin of Color with Tuberous Sclerosis Complex: A Case-Series
Sheenam sethi
Dermatology practical & conceptual, 2021
View PDFchevron_right
Topical Sirolimus 0.2% Gel for the Management of Tuberous Sclerosis Complex-Related Cutaneous Manifestations: An Interim Analysis of Postmarketing Surveillance in Japan
Eric Beresford
Dermatology and Therapy
View PDFchevron_right
Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology
Joyce Teng
Journal of the American Academy of Dermatology, 2015
View PDFchevron_right
Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex
Zabidi Hussin
Cochrane Database of Systematic Reviews, 2014
View PDFchevron_right
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Ferran Torres
Orphanet journal of rare diseases, 2012
View PDFchevron_right
A Triple Laser Combination Treatment for Facial Angiofibromata Management in Tuberous Sclerosis and Literature Review
Konstantinos neamonitos , Foteini Neamonitou
Archives of plastic surgery, 2024
View PDFchevron_right
Tuberous sclerosis complex: the past and the future
Liesbeth De Waele
Pediatric Nephrology, 2014
View PDFchevron_right
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Emir Veledar
Vascular Cell, 2012
View PDFchevron_right
Treatment of angiofibromas of tuberous sclerosis with carbon dioxide laser vaporization
Luiz Leite
Journal of the European Academy of Dermatology and Venereology, 1994
View PDFchevron_right
Facial unilateral angiofibromas: A postzygotic tuberous sclerosis like mutation
Adone Baroni
Indian Journal of Dermatology, Venereology, and Leprology, 2011
View PDFchevron_right
Mucocutaneous changes in tuberous sclerosis complex: A clinical profile of 27 Indian patients
Somenath Sarkar
Indian Journal of Dermatology, 2009
View PDFchevron_right
Giant angiofibromas in tuberous sclerosis complex: A possible role for localized lymphedema in their pathogenesis
Radek Vrtel
Journal of the American Academy of Dermatology, 2012
View PDFchevron_right
Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: Phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial
Eduardo Nagore
Journal of the American Academy of Dermatology, 2015
View PDFchevron_right
Effects of rapamycin on angiomyolipomas in patients with tuberous sclerosis
Ferran Torres
Nefrología : publicación oficial de la Sociedad Española Nefrologia, 2011
View PDFchevron_right
Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis
Luca Toti
Experimental and therapeutic medicine, 2015
View PDFchevron_right